EWTX
Overvalued by 92.8% based on the discounted cash flow analysis.
Market cap | $1.67 Billion |
---|---|
Enterprise Value | - |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $0.0 |
Beta | 0.0 |
Outstanding Shares | 93,398,767 |
Avg 30 Day Volume | 512,487 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 0.0 |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | - |
Enterprise Value to Net Income | - |
Total Debt to Enterprise | - |
Debt to Equity | - |
No data
No data
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need....